Table 4 Univariate analysis of factors influencing overall survival
Overall survival | |||
|---|---|---|---|
Median (95% CI), months | p- value* | ||
Gender | Male | 11.6 (9.2–14.0) | 0.426 |
Female | 13.4 (12.2–14.6) | ||
Age (years) | <65 | 12.0 (10.9–13.1) | 0.608 |
≥65 | 12.1 (9.8–14.4) | ||
Tumor location | Head | 11.6 (9.0–13.0) | 0.413 |
Body/tail | 13.0 (9.5–15.6) | ||
Tumor size(cm) | <4 | 12.7 (9.6–13.8) | 0.664 |
≥4 | 12.0 (9.3–13.4) | ||
Histological differentiation | Well/moderate | 13.4 (10.6–15.6) | 0.717 |
Poor | 8.8 (5.9–25.7) | ||
Not specified | 12.2 (9.5–13.2) | ||
cN classification | N0 | 13.0 (10.6–15.0) | 0.069 |
N1 | 10.7 (8.8–12.7) | ||
CEA (ng/ mL) | <5 | 12.6 (9.8–13.4) | 0.190 |
≥5 | 11.8 (8.3–13.7) | ||
Pretreatment CA 19–9 level (U/mL) | <400 | 12.7 (11.6–15.0) | 0.063 |
≥400 | 9.7 (8.3–12.7) | ||
Concurrent chemotherapy | Capecitabine | 12.5 (10.7–13.7) | 0.655 |
5-FU | 11.6 (8.5–13.8) | ||
Primary tumor response | Responder | 13.6 (8.6–18.9) | 0.165 |
Nonresponder | 11.9 (9.6–13.0) | ||
CA 19–9 percent decrease (%) | <40 | 11.6 (9.0–13.1) | 0.639 |
≥40 | 12.7 (10.7–14.4) | ||
Post-CRT surgery | No | 12.2 (9.8–13.4) | 0.883 |
Yes | 12.0 (5.9–25.7) | ||
Maintenance chemotherapy | No | 10.6 (8.5–12.1) | <0.001 |
Yes | 14.4 (11.7–18.8) |